item1.txt
Net foreign currency transaction and remeasurement losses totaled $0.6 million and $0.7 million, respectively, during the three months ended June 30, 2018 and 2017, and $3.1 million and $1.6 million, respectively, during the nine months ended June 30, 2018 and 2017.
As of June 30, 2018, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
During each of the three and nine months ended June 30, 2017, the Company sold marketable securities with a fair value and amortized cost of $3.6 million each and recognized net losses of less than $0.1 million.
As a result, during these periods, the Company collected cash proceeds of $3.5 million from the sale of marketable securities and reclassified net unrealized holding losses of less than $0.1 million from accumulated other comprehensive income into "Other expenses, net" in the accompanying unaudited Consolidated Statements of Operations as a result of these transactions.
The Company allocated the purchase price of $5.2 million based on the fair value of the assets and liabilities acquired as of the acquisition date, which included $0.3 million of accounts receivable, $2.6 million of customer relationships, $2.7 million of goodwill and $0.7 million of assumed liabilities.
The total cash payment made by the Company as of June 30, 2018 was $12.8 million, net of cash acquired and subject to working capital adjustments.
The revenues and net loss from Tec-Sem included in the Company's consolidated results for the three months ended June 30, 2018 were $4.3 million and $1.6 million, respectively.
During the three months ended June 30, 2018, the net loss included $0.7 million related to the step-up in value of the acquired inventories and $1.0 million related to amortization expense of acquired intangible assets.
During the three months ended June 30, 2018, the Company incurred $0.1 million in transaction costs related to the Tec-Sem acquisition.
Net loss attributable to noncontrolling interest for both the three and nine months ended June 30, 2018 was $0.1 million which represents the 7% minority interest in Tec-Sem.
During the three months ended June 30, 2018, revenue and net income from 4titude recognized in the Company’s results of operations were $3.9 million and less than $0.1 million, respectively.
During the nine months ended June 30, 2018, revenue and net loss from 4titude recognized in the Company’s results of operations were $11.6 million and $1.2 million, respectively.
During the three and nine months ended June 30, 2018, the net income or loss included recurring charges of $1.0 million and $3.1 million, respectively, related to amortization expense of acquired intangible assets.
During the nine months ended June 30, 2018, the net loss also included non-recurring charges of $1.2 million related to the step-up in value of the acquired inventories.
During the nine months ended June 30, 2018, the Company incurred $1.0 million in non-recurring transaction costs with respect to the 4titude acquisition, which were recorded in "Selling, general and administrative" expenses within the accompanying unaudited Consolidated Statements of Operations.
nine months ended June 30, 2018, revenue and net income from PBMMI recognized in the Company’s results of operations were $8.0 million and $0.3 million, respectively.
During the three and nine months ended June 30, 2018, the net income included recurring charges of $0.4 million and $1.2 million, respectively, related to amortization expense of acquired intangible assets.
As of June 30, 2018, the Company completed the annual goodwill impairment test for its five reporting units and determined that no adjustment to goodwill was necessary.
During the nine months ended June 30, 2018, the Company recorded a goodwill increase of $48.6 million primarily related to the acquisitions of 4titude, Tec-Sem and BioSpeciMan which represented the excess of the consideration transferred over the fair value of the net assets acquired.
Amortization expense for intangible assets was $17.7 million and $12.7 million, respectively, during the nine months ended June 30, 2018 and 2017.
During the three months ended June 30, 2018 and 2017, the Company recorded income of $1.3 million and $2.5 million, respectively, representing its proportionate share of UCI’s earnings.
During the nine months ended June 30, 2018 and 2017, the Company recorded income of $4.9 million and $7.7 million, respectively, representing its proportionate share of UCI’s earnings.
Management fee payments received by the Company from UCI were $0.3 million during each of the three months ended June 30, 2018 and 2017.
Management fee payments received by the Company from UCI were $0.8 million during each of the nine months ended June 30, 2018 and 2017.
The Company incurred additional deferred financing costs of $0.4 million during the nine months ended June 30, 2018.
During the nine months ended June 30, 2018, the Company incurred aggregate interest expense of $6.6 million in connection with the term loan borrowings, including $0.3 million of deferred financing costs amortization.
As of June 30, 2018, the Company was in compliance with all covenants and conditions under the term loan agreement.
At June 30, 2018 and September 30, 2017, the Company had cumulative capitalized direct costs of $5.5 million and $4.7 million, respectively, associated with the development of software for its internal use which are included within "Property, plant and equipment, net" in the accompanying unaudited Consolidated Balance Sheets.
During the nine months ended June 30, 2018, the Company capitalized direct costs of $0.8 million associated with the development of software for its internal use.
The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant.
During the nine months ended June 30, 2018 and 2017, the Company granted 35,356 and 43,019 units, respectively, to the members of the Company's Board of Directors, including 26,539 and 28,065 units, respectively, that were compensation-related.
Compensation-related units granted during the nine months ended June 30, 2018 and 2017 are subject to a one-year vesting period starting from the grant date.
The units granted during the nine months ended June 30, 2018 will vest on the date which is one day before the Company's 2019 Annual Meeting of Stockholders.
The units granted during the nine months ended June 30, 2017 vested on January 30, 2018, which was one day before the Company's 2018 Annual Meeting of Stockholders.
During the nine months ended June 30, 2018 and 2017, the Company granted 7,130 and 13,065 units, respectively, related to such deferred annual restricted share awards as well as 1,687 and 1,889 units, respectively, related to deferred quarterly dividends.
Annual restricted share awards granted during the nine months ended June 30, 2018 and 2017 are subject to a one-year vesting period starting from the grant date.
The amount of units granted during the nine months ended June 30, 2018 and 2017 related to deferred quarterly dividends was equal to the value of cash dividends that would be paid on the number of total deferred shares based on the closing price of the Company’s stock on the dividend record date.
The weighted average grant date fair value of restricted stock units granted during the three months ended June 30, 2018 and 2017 was $25.71 and $25.21, respectively.
The weighted average grant date fair value of restricted stock units granted during the nine months ended June 30, 2018 and 2017 was $33.31 and $14.32, respectively.
The fair value of restricted stock units vested during the three months ended June 30, 2018 and 2017 was $2.7 million and $2.9 million, respectively.
The fair value of restricted stock units vested during the nine months ended June 30, 2018 and 2017 was $21.8 million and $14.8 million, respectively.
During the nine months ended June 30, 2018 and 2017, the Company remitted $7.2 million and $4.6 million, respectively, for withholding taxes on vested restricted stock units, of which $0.1 million was paid by the Company during the nine months ended June 30, 2017.
There were no taxes on vested restricted stock units paid by the Company during the nine months ended June 30, 2018.
During the nine months ended June 30, 2018 and 2017, the Company received $7.2 million and $4.6 million, respectively, in cash proceeds from employees to satisfy their tax obligations as a result of share issuances.
As of June 30, 2018, the unrecognized compensation cost related to restricted stock units that are expected to vest is $25.5 million and will be recognized over an estimated weighted average service period of approximately 1.6 years.
The Company maintains an employee stock purchase plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual period, whichever is lower.
The restructuring charges recorded by the Company during the three and nine months ended June 30, 2018 were nominal.
During the three and nine months ended June 30, 2017, the Company recorded restructuring charges of $0.8 million and $2.7 million, respectively.
The charges during the nine months ended June 30, 2017 included $2.2 million in the Brooks Semiconductor Solutions Group segment, $0.2 million in the Brooks Life Sciences segment and $0.3 million related to a company-wide restructuring action.
The Company had one customer that accounted for 10% or more of its consolidated revenue, at 11% during each of the three months ended June 30, 2018 and 2017.
The Company had one customer that accounted for 10% or more of its consolidated revenue, at 12% and 10%, respectively, during the nine months ended June 30, 2018 and 2017.
The Company had non-cancellable contracts and purchase orders for inventory of $148.4 million and $122.0 million, respectively, at June 30, 2018 and September 30, 2017.


item2.txt
Results of Operations- Revenue for the nine months ended June 30, 2018 increased to $620.1 million, or by 21%, as compared to the corresponding period of the prior fiscal year.
Operating income was $71.3 million during the nine months ended June 30, 2018 as compared to $46.7 million for the corresponding period of the prior fiscal year.
Net income was $106.1 million for the nine months ended June 30, 2018 as compared to $45.2 million for the corresponding period of the prior fiscal year.
These increases were partially offset by higher net non-operating expenses of $11.3 million compared to the corresponding period of the prior fiscal year, primarily related to increased interest expense of $6.6 million mainly due to the term loan, higher foreign exchanges losses of $1.5 million and the impact of a $1.8 million gain recorded on the settlement of our investment in Biocision, LLC, or BioCision, during the nine months ended June 30, 2017.
The increase in cash and cash equivalents and marketable securities of $127.7 million was primarily attributable to cash inflows related to proceeds from the term loan of $197.6 million and cash inflows of $42.8 million generated from our operating activities, partially offset by cash outflows related to business acquisitions of $83.0 million, dividend payments of $21.2 million, and capital expenditures of $9.3 million during the nine months ended June 30, 2018.
The $42.8 million of cash generated from operating activities during the nine months ended June 30, 2018 were comprised primarily of earnings of $95.0 million, including net income of $106.1 
We reported revenue of $223.5 million for the three months ended June 30, 2018, compared to $181.7 million for the corresponding period of the prior fiscal year, an increase of $41.8 million, or 23%.
We reported revenue of $620.1 million for the nine months ended June 30, 2018, compared to $511.0 million for the corresponding period of the prior fiscal year, an increase of $109.1 million, or 21%.
The impact of changes in foreign currency exchange rates favorably affected revenue by $4.0 million and $9.0 million, respectively, during the three and nine months ended June 30, 2018 as compared to the corresponding periods of the prior fiscal year.
Our Brooks Semiconductor Solutions Group segment reported revenue of $173.8 million for the three months ended June 30, 2018 compared to $145.0 million for the corresponding period of the prior fiscal year, an increase of 28.8 million, or 20%.
Revenue for the segment was $474.4 million during the nine months ended June 30, 2018, compared to $406.2 million for the corresponding period of the prior fiscal year, an increase of $68.1 million, or 17%.
Our Brooks Life Sciences segment reported revenue of $49.7 million for the three months ended June 30, 2018 compared to $36.8 million for the corresponding period of the prior fiscal year.
Our Brooks Life Sciences segment reported revenue of $145.7 million for the nine months ended June 30, 2018 compared to $104.8 million for the corresponding period of the prior fiscal year.
Brooks Life Sciences internal revenue growth was favorably affected by foreign currency exchange rates by $0.6 million and $2.3 million, respectively, during the three and nine months ended June 30, 2018, as compared to the corresponding periods of the prior fiscal year.
Revenue generated outside the United States was $139.0 million, or 62% of total revenue, for the three months ended June 30, 2018 compared to $111.7 million, or 62% of total revenue, for the corresponding period of the prior fiscal year.
Revenue generated outside the United States was $379.9 million, or 61% of total revenue, for the nine months ended June 30, 2018 compared to $338.1 million, or 66% of total revenue, for the corresponding period of the prior fiscal year.
We reported gross margins of 39.9% for the three months ended June 30, 2018 compared to 39.4% for the corresponding period of the prior fiscal year.
Cost of revenue for the three and nine months ended June 30, 2018 included $1.5 million and $3.4 million, respectively, of charges for amortization related to completed technology as compared to $1.1 million and $3.1 million, respectively, during the corresponding periods of the prior fiscal year.
Cost of revenue for the three and nine months ended June 30, 2018 also included $0.7 million and $1.9 million, respectively of charges related to the inventory step-up in purchase accounting, as compared to $0.1 million and $0.5 million, respectively, during the corresponding periods of the prior fiscal year.
Excluding the purchasing accounting impact related to inventory step-up and the amortization of completed technology, gross margins expanded 0.9 percentage points and 2.5 percentage points, respectively, during the three and nine months ended June 30, 2018 as compared to the corresponding periods of the prior fiscal year.
Our Brooks Semiconductor Solutions Group segment reported gross margins of 40.6% for the three months ended June 30, 2018 as compared to 40.1% for the corresponding period of the prior fiscal year.
Our Brooks Semiconductor Solutions Group segment reported gross margins of 41.2% for the nine months ended June 30, 2018 as compared to 38.1% for the corresponding period of the prior fiscal year.
Cost of revenue for the three and nine months ended June 30, 2018 included $1.2 million and $2.3 million, respectively, of charges for amortization related to completed technology as compared to $0.6 million and $1.9 million, respectively, incurred during the corresponding periods of the prior fiscal year.
Excluding the purchase accounting impact and the amortization of completed technology, margins expanded 1.2 percentage points and 3.2 percentage points, respectively, during the three and nine months ended June 30, 2018 as compared to the corresponding periods of the prior fiscal year.
Our Brooks Life Sciences segment reported gross margins of 37.4% for the three months ended June 30, 2018 as compared to 36.7% for the corresponding period of the prior fiscal year.
Our Brooks Life Sciences segment reported gross margins of 36.6% for the nine months ended June 30, 2018 as compared to 36.4% for the corresponding period of the prior fiscal year.
Cost of revenue for the three and nine months ended June 30, 2018 included $0.4 million and $1.1 million, respectively, of charges for amortization related to completed technology as compared to $0.4 million and $1.2 million, respectively, incurred during the corresponding periods of the prior fiscal year.
Excluding the purchasing accounting impact and the amortization of completed technology, margins increased 0.1 percentage points and 0.2 percentage points for the three and nine months ended June 30, 2018, respectively as compared to the corresponding periods of the prior fiscal year.
Research and development expenses were $14.2 million and $40.5 million, respectively, during the three and nine months ended June 30, 2018 as compared to $12.0 million and $34.1 million, respectively, during the corresponding periods of the prior fiscal year.
The increase of $6.4 million during the nine months ended June 30, 2018 as compared to the corresponding periods of the prior fiscal year reflects greater investments in the 2018 period of $3.7 million within the Brooks Semiconductor Solutions Group segment and $2.6 million within the Brooks Life Sciences segment.
Higher research and development expenses during the three and nine months ended June 30, 2018 as compared to the same periods of prior fiscal year were primarily attributable to higher employee related costs and project spending to support new product development and the growth of our business as well as research and development costs associated with new acquisitions made during the nine months ended June 30, 2018.
The charges during the nine months ended June 30, 2017 included $2.2 million in the Brooks Semiconductor Solutions Group segment, $0.2 million in the Brooks Life Sciences segment and $0.3 million related to a company-wide restructuring action.
The $1.4 million increase was primarily attributable to higher foreign currency exchange losses of $1.5 million recognized during the nine months ended June 30, 2018 as compared to the corresponding period of the prior year.
During the nine months ended June 30, 2017, we incurred losses of $0.5 million from our investment in BioCision which was settled during the first quarter of fiscal year 2017 as a part of the non-cash consideration for the acquisition of Cool Lab in November 2016.
was primarily attributable to cash inflows of $197.6 million related to proceeds from the term loan and cash inflows of $42.8 million generated from our operating activities, partially offset by cash outflows related to business acquisitions of $83.0 million, dividend payments of $21.2 million, and capital expenditures of $9.3 million during the nine months ended June 30, 2018.
Cash flows provided by operating activities were $42.8 million during the nine months ended June 30, 2018, comprised primarily of earnings of $95.0 million, including net income of $106.1 million and the impact of non-cash related charges of $11.1 million.
Cash flows provided by operating activities were $61.4 million during the nine months ended June 30, 2017 and comprised primarily of earnings of $68.3 million, including net income of $45.2 million and the impact of non-cash related charges of $23.1 million.
Cash used in investing activities was $141.9 million during the nine months ended June 30, 2018 as compared to $9.0 million during the corresponding period of the prior fiscal year.
Cash used in investing activities of $141.9 million during the nine months ended June 30, 2018 included cash payments of $83.0 million for acquisitions, $58.3 million for the purchases of marketable securities and $9.3 million of capital expenditures, partially offset by cash inflows from sales and maturities of marketable securities of $8.5 million.
Cash used in investing activities of $9.0 million during the nine months ended June 30, 2017 included primarily $5.3 million for the acquisition of CoolLab and $6.8 million of capital expenditures, offset by $3.6 million of proceeds from sales and maturities of marketable securities.
Capital expenditures were $9.3 million during the nine months ended June 30, 2018 as compared to $6.8 million during the corresponding period of the prior fiscal year.


item3.txt
Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies.
Sales in currencies other than the U.S. dollar were approximately 30% and 35% of our total sales, respectively, during the nine months ended June 30, 2018 and 2017.
Such balances were approximately $154.9 million and $51.6 million, respectively, at June 30, 2018 and September 30, 2017, and related to the Euro, British Pound and a variety of Asian currencies.
We incurred foreign currency losses of $3.1 million and $1.6 million, respectively, during the nine months ended June 30, 2018 and 2017, which related to the currency fluctuation on these balances between the time the transaction occurred and the ultimate settlement of the transaction.


part2.txt
The timing and amount of any shares repurchased are based on market and business conditions, legal requirements and other factors and may be commenced or suspended at any time at our discretion.
There were no shares repurchased under this program during the nine months ended June 30, 2018 and there are no shares repurchased under this program since its inception.


